Archives of Dermatological Research

, Volume 304, Issue 10, pp 839–845 | Cite as

Role of translocator protein in melanoma growth and progression

  • Tatiana Ruksha
  • Maria Aksenenko
  • Vassilios Papadopoulos
Short Communication

Abstract

The 18 kDa translocator protein (TSPO) is a primarily mitochondrial protein that participates in steroid biosynthesis, cell proliferation, differentiation, apoptosis, and the regulation of mitochondrial function in general. TSPO has been implicated in carcinogenesis via its ability to transport cholesterol into mitochondria to meet the increased energy needs of tumor cells. The purpose of this study was to investigate TSPO involvement in melanoma pathogenesis. TSPO expression in melanoma and melanocytic nevi was analyzed by immunohistochemistry and real-time PCR, and TSPO levels were correlated to the invasiveness of the tumor. The number of TSPO-positive melanoma samples increased with tumor progression irrespective of age or gender of patients. Similar findings were obtained while examining TSPO expression levels in relation to the Clark invasion stage of the tumor. Indeed, the immunohistochemical index was elevated in invasive tumors characterized as Clark level V compared to those characterized as levels I and II. Besides, the elevation of immunohistochemical index was accompanied with a shift of homogeneous cytoplasmic subcellular expression pattern of the protein to nuclear and perinuclear. Taken together, these results suggest TSPO participation in melanoma growth and progression.

Keywords

Cutaneous melanoma Melanocytic nevus TSPO 

References

  1. 1.
    Aplin AE, Kaplan FM, Shao Y (2011) Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 131:1817–1820PubMedCrossRefGoogle Scholar
  2. 2.
    Batarseh A, Li J, Papadopoulos V (2010) Protein kinase C epsilon regulation of translocator protein (18 kDa) Tspo gene expression is mediated through a MAPK pathway targeting STAT3 and c-Jun transcription factors. Biochemistry 49:4766–4778PubMedCrossRefGoogle Scholar
  3. 3.
    Batarseh A, Papadopoulos V (2010) Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol 327:1–12PubMedCrossRefGoogle Scholar
  4. 4.
    Braestrup C, Squires RF (1978) Specific benzodiazepine receptors in rat brain characterized by high-affinity [3H] diazepam binding. Proc Natl Acad Sci USA 74:3805–3809CrossRefGoogle Scholar
  5. 5.
    Bribes E, Carriere D, Goubet C et al (2004) Immunohistochemical assessment of the peripheral benzodiazepine receptor in human tissues. J Histochem Cytochem 52:19–28PubMedCrossRefGoogle Scholar
  6. 6.
    Bribes E, Galiegue S, Bourrie B, Casellas P (2003) Involvement of the peripheral benzodiazepine receptor in the development of cutaneous pathology in Mrl/Lpr mice. Immunol Lett 85:13–18PubMedCrossRefGoogle Scholar
  7. 7.
    Chen N, Ma W, Huang C, Dong Z (1999) Translocation of protein kinase C epsilon and protein kinase C delta to membrane is required for ultraviolet B-induced activation of mitogen-activated protein kinases and apoptosis. J Biol Chem 274:15389–15394PubMedCrossRefGoogle Scholar
  8. 8.
    Cornu P, Benavides J, Scatton B, Hauw J, Philippon J (1992) Increase in ω3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumors. A quantitative autoradiography study. Acta Neurochir 119:146–152CrossRefGoogle Scholar
  9. 9.
    Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRefGoogle Scholar
  10. 10.
    Delavoie F, Li H, Hardwick M et al (2003) In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 42:4506–4519PubMedCrossRefGoogle Scholar
  11. 11.
    Fafalios A, Akhavan A, Parwani AV (2009) Translocator protein blockade reduces prostate tumor growth. Clin Cancer Res 15:6177–6184PubMedCrossRefGoogle Scholar
  12. 12.
    Fan J, Lindemann P, Feuilloley M, Papadopoulos V (2012) Structural and functional evolution of the translocator protein (18 kDa). Curr Mol Med 12:369–386 Google Scholar
  13. 13.
    Favreau F, Rossard L, Zhang K et al (2009) Expression and modulation of translocator protein and its partners by hypoxia reoxygenation or ischemia and reperfusion in porcine renal models. Am J Physiol Renal Physiol 297:F177–F190PubMedCrossRefGoogle Scholar
  14. 14.
    Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20:183–189PubMedCrossRefGoogle Scholar
  15. 15.
    Galiegue S, Casellas P, Kramar A et al (2004) Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res 10:2058–2064PubMedCrossRefGoogle Scholar
  16. 16.
    Haass NK, Smalley KS (2009) Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther 13:283–296PubMedCrossRefGoogle Scholar
  17. 17.
    Han Z, Slack SR, Li W, Papadopoulos V (2003) Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colon and prostate tumor progression. J Recept Signal Transduct Res 23:225–238PubMedCrossRefGoogle Scholar
  18. 18.
    Hardwick M, Fertikh D, Culty M et al (1999) Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 59:831–842PubMedGoogle Scholar
  19. 19.
    Hocker TL, Singh MK, Tsao H (2008) Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128:2575–2595PubMedCrossRefGoogle Scholar
  20. 20.
    Jonjic N, Zamolo G, Stifter S et al (2003) Cytomorphological variations, proliferation and angiogenesis in the prognosis of cutaneous melanoma. Clin Exp Dermatol 28:310–314PubMedCrossRefGoogle Scholar
  21. 21.
    Junttila MR, Li S-P, Westermarck J (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22:954–965PubMedCrossRefGoogle Scholar
  22. 22.
    Konigsrainer I, Vogel UF, Beckert S et al (2007) Increased translocator protein (TSPO) mRNA levels in colon but not in rectum carcinoma. Eur Surg Res 39:359–363PubMedCrossRefGoogle Scholar
  23. 23.
    Li H, Yao Z, Degenhardt B et al (2001) Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci USA 98:1267–1272PubMedCrossRefGoogle Scholar
  24. 24.
    McCarty KS Jr, Miller LS, Cox EB et al (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721PubMedGoogle Scholar
  25. 25.
    Miettinen H, Kononen J, Haapasalo H et al (1995) Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 55:2691–2695PubMedGoogle Scholar
  26. 26.
    Morgan J, Oseroff AR, Cheney RT (2004) Expression of the peripheral benzodiazepine receptor is decreased in skin cancers in comparison with normal skin. Br J Dermatol 151:846–856PubMedCrossRefGoogle Scholar
  27. 27.
    Nagler R, Ben-Izhak O, Savulescu D et al (2010) Oral cancer, cigarette smoke and mitochondrial 18 kDa translocator protein (TSPO)—in vitro, in vivo, salivary analysis. Biochim Biophys Acta 1802:454–461PubMedCrossRefGoogle Scholar
  28. 28.
    Papadopoulos V, Baraldi M, Guilarte TR et al (2006) Translocator Protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402–409PubMedCrossRefGoogle Scholar
  29. 29.
    Poynter JN, Elder JT, Fullen DR et al (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267–273PubMedCrossRefGoogle Scholar
  30. 30.
    Schafer M, Werner S (2011) The cornified envelope: a first line of defense against reactive oxygen species. J Invest Dermatol 131:1409–1411PubMedCrossRefGoogle Scholar
  31. 31.
    Stoebner PE, Carayon P, Casellas P et al (2001) Transient protection by peripheral benzodiazepine receptors during the early events of ultraviolet light-induced apoptosis. Cell Death Differ 8:747–753PubMedCrossRefGoogle Scholar
  32. 32.
    Stoebner PE, Carayon P, Penarier G et al (1999) The expression of peripheral benzodiazepine receptors in human skin: the relationship with epidermal cell differentiation. Br J Dermatol 140:1010–1016PubMedCrossRefGoogle Scholar
  33. 33.
    Thompson JF, Soong S-J, Balch CM et al (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol 29:2199–2205PubMedCrossRefGoogle Scholar
  34. 34.
    Trappey A, Fernando A, Gaur R et al (2010) The shady side of sunlight: current understanding of the mechanisms underlying UV-induction of skin cancers. Front Biosci (Schol Ed) 2:11–17CrossRefGoogle Scholar
  35. 35.
    Veenman L, Papadopoulos V, Gavish M (2007) Channel-like functions of the 18 kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des 13:2385–2405PubMedCrossRefGoogle Scholar
  36. 36.
    Yeliseev AA, Kaplan S (1995) A sensory transducer homologous to the mammalian-peripheral type benzodiazepine receptor regulates photosynthetic membrane complex formation in Rhodobacter sphaeroides 2.4.1. J Biol Chem 270:21167–21175PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Tatiana Ruksha
    • 1
    • 2
  • Maria Aksenenko
    • 1
  • Vassilios Papadopoulos
    • 2
    • 3
  1. 1.Department of PathophysiologyKrasnoyarsk State Medical UniversityKrasnoyarskRussia
  2. 2.Department of Biochemistry and Molecular and Cellular BiologyGeorgetown University Medical CenterWashingtonUSA
  3. 3.The Research Institute of the McGill University Health Center and Departments of Medicine, Biochemistry, Pharmacology and TherapeuticsMcGill UniversityMontrealCanada

Personalised recommendations